Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2003
we propose to randomize patients with hormone resistant prostate cancer between docetaxel/estramustine/prednisone and docetaxel/prednisone in a phase II study. The principal endpoint will be the efficacy in term of PSA response.
Epistemonikos ID: 02103ee0c1bc0290334f261d653be7af145ab11a
First added on: May 04, 2024